Atlas of datasets from our hematological models
Diag2Tec provides access to high-value datasets generated from its models :
- hematologic cancer cell lines,
- plasma cell differentiation model,
- and patient-derived primary samples.
Among these datasets, there are flow cytometry data, clinical data, RNAsequencing from tumor and non-tumor cells, exome sequencing, single cell RNAseq, and other on request.
These datasets, developed internally or in collaboration with leading hospital partners, can be leveraged to accelerate research and support data-driven programs.
Access to Exclusive Cohorts
We offer the opportunity to access or generate new datasets from well-characterized patient cohorts including rare and clinically annotated samples :
- Longitudinal collections of pre- and post-treatment with Daratumumab from multiple myeloma samples
- Longitudinal collection of pre- and post-treatment with CAR-T therapies for B-cell lymphoma and multiple myeloma
The characterization of these cohorts enables the investigation of treatment response, resistance mechanisms, and disease evolution.
Custom Genomic Characterization
We provide comprehensive in-house genomic characterization of our models at baseline or following ex vivo treatments. Our capabilities include RNA sequencing, single-cell RNAseq, whole-exome sequencing, and other specific epigenetic approaches. We provide advanced multi-omics analyses, including specific profiling for immunotherapy studies.
By integrating genomic, biological, and clinical data, we generate high-value, actionable insights to support biomarker discovery, mechanism-of-action studies, and precision medicine strategies.